Canine Transitional Cell Carcinoma Management

Transitional cell carcinoma (TCC) of the canine urinary bladder is the most prevalent malignant neoplasm affecting the lower urinary tract in dogs. It is characterised by aggressive local invasion through the bladder wall, frequent regional lymph node involvement and a high propensity for distant metastasis. Clinical signs typically include haematuria, pollakiuria and dysuria, often prompting ultrasonography or computed tomography to evaluate tumour extent and plan management. Definitive diagnosis relies on cytological examination or transmural biopsy, while staging encompasses thoracic radiography and regional lymph node assessment. Therapeutic approaches integrate surgery—when feasible—systemic chemotherapy, cyclooxygenase-2 (COX-2) inhibitors and emerging targeted therapies aimed at molecular alterations such as the BRAF V595E mutation. Minimally invasive techniques, including electrochemotherapy, are under investigation for enhanced local tumour control with minimal morbidity. Despite incremental improvements in median survival, outcomes remain guarded. Canine TCC thus serves as both a clinical challenge in veterinary practice and a valuable comparative model for human urothelial carcinoma research.

Research from Nature Portfolio

Recent clinical utilisation of electrochemotherapy combining intravenous bleomycin with electric pulses has demonstrated safety and local efficacy in dogs with spontaneous bladder carcinoma. More than 60% of treated animals achieved a complete response, with extended disease-free intervals and minimal perioperative complications. Parallel mechanistic investigations into BRAF-mutant urothelial carcinoma have elucidated that activation of the ERK MAPK pathway drives overexpression of COX-2 and consequent prostaglandin E2 production. This insight identifies potential targets for anti-inflammatory and pathway-directed therapies to disrupt tumour-promoting inflammation.

Canine Transitional Cell Carcinoma Management publication trend

The graph below shows the total number of articles in canine transitional cell carcinoma management across all publications each year (not limited to Nature Index journals).

Technical terms

Transitional cell carcinoma (TCC): A malignant epithelial tumour originating from the bladder urothelium, noted for invasive growth and metastatic potential.

Electrochemotherapy (ECT): A local cancer therapy that uses electric pulses to increase cell membrane permeability and enhance uptake of cytotoxic drugs.

Cyclooxygenase-2 (COX-2): An inducible enzyme responsible for prostaglandin synthesis, commonly upregulated in tumours and targeted by non-steroidal anti-inflammatory agents.

Prostaglandin E2 (PGE2): A lipid mediator produced via COX-2 that promotes inflammation, angiogenesis and tumour progression.

BRAF V595E mutation: A canine analogue of the human V600E mutation in the BRAF gene, leading to constitutive activation of the MAPK pathway.

MAPK (mitogen-activated protein kinase) pathway: A signalling cascade regulating cell proliferation, survival and differentiation; dysregulation is common in cancer.

References

1. Vaccination against Extracellular Vimentin for Treatment of Urothelial Cancer of the Bladder in Client-Owned Dogs. Cancers (2023).
2. Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs. Scientific Reports (2023).
3. Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma. Scientific Reports (2020).
4. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target. International Journal of Molecular Sciences (2021).
5. Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy. Veterinary Sciences (2022).